New Risk • Jun 01
New major risk - Revenue and earnings growth Earnings have declined by 5.3% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.3% per year over the past 5 years. Minor Risks Profit margins are more than 30% lower than last year (17% net profit margin). Market cap is less than US$100m (₩57.4b market cap, or US$38.1m). New Risk • Apr 03
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 33% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (21% net profit margin). Market cap is less than US$100m (₩57.6b market cap, or US$38.2m). Announcement • Mar 17
P&K Skin Research Center Co., Ltd., Annual General Meeting, Mar 31, 2026 P&K Skin Research Center Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 22, uisadang-daero, yeongdeungpo-gu, seoul South Korea Buy Or Sell Opportunity • Dec 22
Now 20% overvalued Over the last 90 days, the stock has fallen 11% to ₩2,585. The fair value is estimated to be ₩2,146, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.9% over the last 3 years. Earnings per share has grown by 4.3%. Declared Dividend • Nov 08
Dividend of ₩40.00 announced Dividend of ₩40.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 20th April 2026 Dividend yield will be 1.5%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is well covered by both earnings (16% earnings payout ratio) and cash flows (18% cash payout ratio). The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. Earnings per share has grown by 1.4% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Nov 07
P&K Skin Research Center Co., Ltd. announces Annual dividend, payable on April 20, 2026 P&K Skin Research Center Co., Ltd. announced Annual dividend of KRW 40.0000 per share payable on April 20, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Valuation Update With 7 Day Price Move • Jul 15
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩3,235, the stock trades at a trailing P/E ratio of 13.6x. Average trailing P/E is 16x in the Life Sciences industry in South Korea. Total loss to shareholders of 37% over the past three years. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩2,600, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 18x in the Life Sciences industry in South Korea. Total loss to shareholders of 37% over the past three years. Announcement • Mar 18
P&K Skin Research Center Co., Ltd., Annual General Meeting, Mar 31, 2025 P&K Skin Research Center Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 22, uisadang-daero, yeongdeungpo-gu, seoul South Korea Upcoming Dividend • Dec 20
Upcoming dividend of ₩30.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 1.4%. Lower than top quartile of South Korean dividend payers (3.9%). Higher than average of industry peers (1.0%). New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩63.5b market cap, or US$44.2m). Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₩2,015, the stock trades at a trailing P/E ratio of 10.9x. Average trailing P/E is 12x in the Life Sciences industry in South Korea. Total loss to shareholders of 55% over the past three years. New Risk • Sep 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 1.9% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (9.1% average weekly change). Market cap is less than US$100m (₩76.4b market cap, or US$56.8m). Buy Or Sell Opportunity • Aug 21
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 14% to ₩2,540. The fair value is estimated to be ₩3,196, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last year. Earnings per share has declined by 34%. Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₩2,320, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 63% over the past three years. Buy Or Sell Opportunity • Aug 05
Now 27% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩2,320. The fair value is estimated to be ₩3,195, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last year. Earnings per share has declined by 34%. Buy Or Sell Opportunity • Jul 01
Now 19% overvalued after recent price rise Over the last 90 days, the stock has risen 13% to ₩3,270. The fair value is estimated to be ₩2,747, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last year. Earnings per share has declined by 34%. Buy Or Sell Opportunity • Jun 28
Now 22% overvalued after recent price rise Over the last 90 days, the stock has risen 16% to ₩3,355. The fair value is estimated to be ₩2,745, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has declined by 13% over the last year. Earnings per share has declined by 34%. Valuation Update With 7 Day Price Move • Jun 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩3,280, the stock trades at a trailing P/E ratio of 21x. Average trailing P/E is 21x in the Life Sciences industry in South Korea. Total loss to shareholders of 42% over the past three years. New Risk • Jan 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩73.7b market cap, or US$54.7m). Buying Opportunity • Jan 09
Now 20% undervalued Over the last 90 days, the stock is up 1.8%. The fair value is estimated to be ₩3,191, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 2.7% over the last year. Earnings per share has declined by 2.8%. Upcoming Dividend • Dec 20
Inaugural dividend of ₩35.00 per share Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. This is the first dividend for P&K Skin Research Center since going public. The average dividend yield among industry peers is 0.9%. Announcement • Nov 17
P&K Skin Research Center Co., Ltd. (KOSDAQ:A347740) announces an Equity Buyback for ¥3,000 million worth of its shares. P&K Skin Research Center Co., Ltd. (KOSDAQ:A347740) announces a share repurchase program. Under the program, the company will repurchase up to KRW 3,000 million worth of its shares pursuant to a contract with SK Securities Co., LTD. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on November 14, 2024. As of November 14, 2023, the company had no shares in treasury within scope available for dividend and had no shares in treasury through other repurchase. New Risk • Sep 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (₩89.0b market cap, or US$67.0m). New Risk • Sep 01
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Market cap is less than US$100m (₩96.2b market cap, or US$72.6m). Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩4,110, the stock trades at a trailing P/E ratio of 19.2x. Average trailing P/E is 21x in the Life Sciences industry in South Korea. Total loss to shareholders of 11% over the past year. Upcoming Dividend • Dec 21
Inaugural dividend of ₩37.50 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 19 April 2023. This is the first dividend for P&K Skin Research Center since going public. The average dividend yield among industry peers is 0.7%. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₩5,850, the stock trades at a trailing P/E ratio of 26.2x. Average trailing P/E is 28x in the Life Sciences industry in South Korea. Total loss to shareholders of 1.7% over the past year. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment improved over the past week After last week's 21% share price gain to ₩6,500, the stock trades at a trailing P/E ratio of 7.3x. Average trailing P/E is 28x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past year. Valuation Update With 7 Day Price Move • Jul 11
Investor sentiment improved over the past week After last week's 21% share price gain to ₩16,600, the stock trades at a trailing P/E ratio of 18.6x. Average trailing P/E is 29x in the Life Sciences industry in South Korea. Total loss to shareholders of 30% over the past year. Valuation Update With 7 Day Price Move • Jun 16
Investor sentiment deteriorated over the past week After last week's 15% share price decline to ₩14,150, the stock trades at a trailing P/E ratio of 15.9x. Average trailing P/E is 24x in the Life Sciences industry in South Korea. Total loss to shareholders of 43% over the past year. Is New 90 Day High Low • Feb 15
New 90-day low: ₩20,750 The company is down 15% from its price of ₩24,400 on 17 November 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 6.0% over the same period. Is New 90 Day High Low • Jan 29
New 90-day low: ₩20,900 The company is down 6.0% from its price of ₩22,250 on 30 October 2020. The South Korean market is up 33% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 23% over the same period.